Lantern Pharma Inc. (LTRN) — Financial statements
Income statement, balance sheet, and cash flow for Lantern Pharma Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.02 | 0.00↓100.0% | 0.17 | 0.00 | 0.00 | |
| Gross Profit | -0.02 | 0.00↑100.0% | -0.17 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 11,514↑71302.4% | 16↑35.6% | 12↑38.3% | 9↑13.6% | 8 | |
| General & Administrative Expenses | 6,464↑106034.3% | 6↑1.8% | 6↑2.6% | 6↑16.1% | 5 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 6,464↑106034.3% | 6↑1.8% | 6↑2.6% | 6↑16.1% | 5 | |
| Other Expenses | -17,961 | 0.00↑100.0% | -0.17 | 0.00 | 0.00 | |
| Operating Expenses | 18↓19.1% | 22↑25.5% | 18↑22.7% | 14↑14.6% | 13 | |
| Total Costs & Expenses | 18↓19.1% | 22↑24.3% | 18↑23.9% | 14↑14.6% | 13 | |
| Operating Results | ||||||
| Operating Income | -18↑19.1% | -22↓24.3% | -18↓23.9% | -14↓14.6% | -13 | |
| Depreciation & Amortization | 0.02↓0.0% | 0.02↓90.1% | 0.17↑1634.4% | 0.01↑49.1% | 0.01 | |
| EBITDA | -18↑19.1% | -22↓40.6% | -16↓9.5% | -14↓14.6% | -13 | |
| EBIT | -18↑19.1% | -22↓39.2% | -16↓10.6% | -14↓14.6% | -13 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.44↓41.0% | 0.74↓3.0% | 0.77 | 0.00↓100.0% | 0.07 | |
| Interest Income | 0.44↓41.0% | 0.74↓3.0% | 0.77↑274.5% | 0.20↑200.8% | 0.07 | |
| Interest Expense | 0.00 | 0.00 | 0.00↓100.0% | 0.20 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00↑100.0% | -2 | 0.00 | 0.00 | |
| Other Income / Expenses | 0.86↓40.1% | 1↓25.1% | 2↑1008.8% | 0.17↓24.4% | 0.23 | |
| Income Before Tax | -17↑17.6% | -21↓30.2% | -16↓11.9% | -14↓15.3% | -12 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -17↑17.6% | -21↓30.2% | -16↓11.9% | -14↓15.3% | -12 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -17↑17.6% | -21↓30.2% | -16↓11.9% | -14↓15.3% | -12 | |
| Bottom-Line Net Income | -17↑17.6% | -21↓30.2% | -16↓11.9% | -14↓15.3% | -12 | |
| EPS (Basic) | -1.57↑99.9% | -1,930.92↓131255.1% | -1.47↓12.2% | -1.31↓15.9% | -1.13 | |
| EPS (Diluted) | -1.57↑99.9% | -1,930.92↓131255.1% | -1.47↓12.2% | -1.31↓15.9% | -1.13 | |
| Weighted Average Shares | 11↑1.3% | 11↓0.7% | 11↓0.1% | 11↓0.5% | 11 | |
| Weighted Average Diluted Shares | 11↑1.3% | 11↓0.7% | 11↓0.1% | 11↓0.5% | 11 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.